Becker's Healthcare December 19, 2025
The Trump administration finalized agreements Dec. 19 with nine pharmaceutical manufacturers to offer U.S. patients prescription drug prices aligned with the lowest rates paid by other developed nations.
The companies — Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi — agreed to provide “most-favored-nation” pricing on various therapies, including treatments for cancer, Type 2 diabetes, rheumatoid arthritis, HIV, hepatitis B and C, and asthma. Medicaid programs in all 50 states will gain access to these pricing arrangements, according to a White House news release.
The agreements also include substantial discounts for direct-to-patient sales through TrumpRx. Examples include Sanofi’s blood thinner Plavix, reduced from $756 to $16; Gilead’s hepatitis C drug Epclusa, cut from $24,920...
Today's Sponsors
Today's Sponsor